What is Acobiom?
Acobiom operates at the intersection of bioinformatics and clinical diagnostics, specializing in the discovery of novel biomarkers. The company provides a comprehensive suite of services, including biostatistics and molecular analysis, designed to facilitate personalized medical care. Its flagship innovation, GemciTest, represents a significant advancement in non-invasive diagnostics, specifically engineered to predict patient response to Gemcitabine in the treatment of pancreatic cancer. By focusing on blood-based testing, Acobiom effectively reduces the need for invasive procedures, positioning itself as a key player in the evolving landscape of precision oncology.
How much funding has Acobiom raised?
Acobiom has raised a total of $1.3M across 1 funding round:
Unspecified
$1.3M
Unspecified (2013): $1.3M with participation from Bpifrance
Key Investors in Acobiom
Bpifrance
A French public investment bank that provides financing and support to companies at every stage of their development, with a strong focus on innovation and industrial growth.
What's next for Acobiom?
With the recent influx of capital, Acobiom is well-positioned to expand its research and development pipeline, focusing on the validation of new biomarkers for broader therapeutic applications. The strategic roadmap likely involves scaling the deployment of GemciTest across international clinical markets and enhancing its bioinformatics infrastructure to support larger-scale genomic studies. As the company transitions into a more mature phase of enterprise-level operations, the focus will shift toward establishing strategic partnerships with pharmaceutical entities and healthcare providers to integrate its diagnostic solutions into standard oncology protocols. This growth phase is expected to solidify Acobiom's influence in the precision medicine market, driving long-term value through technological differentiation and clinical utility.
See full Acobiom company page
